NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Baxiva AG

Baxiva AG

Private
SchlierenHealthcare & Life Scienceshttps://www.baxiva.com/

Last Round

Accelerator

Feb 23, 2026

Total Funding Raised

$3.19M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Baxiva AG is a biotechnology company that develops next-generation glycoconjugate vaccines to prevent serious infections caused by Gram-negative bacteria.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

glycoconjugate vaccinebiotechnologyvaccine platformdrug discoveryextraintestinal pathogenic Escherichia coliExPECGram-negative bacteriabiotech startupvaccine developmentnanoparticle carrierantimicrobial resistancebiotech licensingpharma partneringwet labpreclinical research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Baxiva AG Comparables

Compare Baxiva AG with similar companies based on industry and business-model similarity.

Baxiva AG comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Omniose
83%
Glycovax Pharma
81%
Matrivax Research & Development Corporation
78%

Baxiva AG Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorFeb 23, 2026
GrantAug 22, 2025

Key People

Founding team and executive leadership

Tim Keys

Chief Executive Officer

Executive Team

Johannes K. Mühl

Chief Operating Officer

Executive Team

Baxiva AG Investors

Notable investors and investment history

Baxiva AG investors
InvestorRounds
CARB-XGrant
Venture KickAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 3, 2026

    Monthly visitors increased 69% MoM, reaching 1.4K.

  • Mar 3, 2026

    Monthly visitors grew 2090% MoM, from 39 to 854.

Baxiva AG Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Baxiva AG Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Baxiva AG's valuation, stock price, and market status.

Firmographic Details

HeadquartersSchlieren
Employee Range8
Year Founded2025
Last FundingFeb 23, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.